E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary Hyperoxaluria |
Hiperoxaluria Primaria |
|
E.1.1.1 | Medical condition in easily understood language |
Primary Hyperoxaluria is where the liver overproduces oxalate. As a result calcium-oxalate crystals form in the urinary system and lead to the formation of kidney stones and impaired kidney function. |
Hiperoxaluria primaria se produce cuando el hígado sobreproduce oxalato. Como resultado los cristales de oxalato de calcio en el sistema urinario forman piedras en el riñon dañando la función renal |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020703 |
E.1.2 | Term | Hyperoxaluria |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety of nedosiran in neonates, infants, and young children with PH and relatively intact renal function based upon eGFR and serum creatinine |
Caracterizar la seguridad de Nedosiran en neonatos, lactantes y niños con HP y función renal relativamente intacta con base en la TFGe y la creatinina sérica |
|
E.2.2 | Secondary objectives of the trial |
1. To characterize the efficacy of nedosiran in neonates, infants, and young children with PH and relatively intact renal function based upon eGFR and serum creatin 2. To characterize the PK of nedosiran in neonates, infants, and young children with PH and relatively intact renal function based upon eGFR and serum creatinineine 3. To assess the efficacy of nedosiran in neonates, infants, and young children with PH and relatively intact renal function based upon eGFR and serum creatinine 4. To evaluate the effect of nedosiran on eGFR in neonates, infants, and young children with PH and relatively intact renal function based upon eGFR and serum creatinine |
Evaluar la eficacia de Nedosiran en neonatos, lactantes y niños con HP y función renal relativamente intacta con base en la TFGe y la creatinina sérica Caracterizar la farmacinética de Nedosiran en neonatos, lactantes y niños con HP y función renal relativamente intacta con base en la TFGe y la creatinina sérica Evaluar la eficacia de Nedosiran en neonatos, lactantes y niños con HP y función renal relativamente intacta con base en la TFGe y la creatinina sérica Evaluar el efecto de Nedosiran en la TFGe en neonatos, lactantes y niños con HP y función renal relativamente intacta con base en la TFGe y la creatinina sérica |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Estimated glomerular filtration rate (eGFR) at Screening ≥ 30 mL/min normalized to 1.73 m2 body surface area (BSA). 2. Average spot Uox-to-creatinine ratio at Screening above 2 times the 95th percentile for age based on Matos et al, 1999: > 0.44 mol/mol in participants < 6 months > 0.34 mol/mol in participants from 6 months to <12 months > 0.26 mol/mol in participants 12 months to < 2 years > 0.20 mol/mol in participants from 2 to < 3 years and > 0.16 mol/mol in participants from 3 to 5 years |
1. Tasa de filtración glomerular estimada (TFGe) en la selección ≥ 30 mlL/min normalizada a 1,73 m2 de area de superficie corporal (ASC). 2. Proporcion media de oxalato-creatinina de las muestras puntuales de orina en la selección 2 veces por encima del percentil 95 para la edad según Matos et al, 1999: > 0,44 mol / mol en participantes <6 meses > 0,34 mol / mol en participantes de 6 meses a <12 meses > 0,26 mol / mol en participantes de 12 meses a <2 años > 0,20 mol / mol en participantes de 2 a <3 años y > 0,16 mol / mol en participantes de 3 a 5 años |
|
E.4 | Principal exclusion criteria |
1. Renal or hepatic transplantation (prior or planned within the study period) 2. Plasma oxalate (Pox) > 30 µmol/L at Screening 3.Documented evidence of clinical manifestations of severe systemic oxalosis (including preexisting retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations) |
1. Trasplante renal o hepático (previo o planificado dentro del período de estudio) 2. Oxalato plasmático (Pox)> 30 µmol / L en la selección 3.Evidencia documentada de manifestaciones clínicas de oxalosis sistémica grave (incluidas calcificaciones retinianas, cardíacas o cutáneas preexistentes, o antecedentes de dolor óseo severo, fracturas patológicas o deformaciones óseas) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- The incidence and nature of TEAEs and SAEs - Change from Baseline in 12-lead ECG, physical examination findings, vital sign assessments, and clinical laboratory tests |
La incidencia y las características de los acontecimientos adversos surgidos durante el tratamiento (AAST) y los acontecimientos adversos graves (AAG) Cambio desde el inicio en el ECG de 12 derivaciones, los hallazgos en las exploraciones físicas, las evaluaciones de las constantes vitales y los análisis clínicos de laboratorio |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Descriptive statistics will be provided for absolute values and changes from baseline in physical examination findings, vital sign measurements, ECGs, and clinical laboratory results at each timepoint. |
Se proporcionarán estadísticas descriptivas para los valores absolutos y los cambios desde el inicio en los hallazgos del examen físico, mediciones de signos vitales, ECG y resultados de laboratorio clínico en cada punto temporal |
|
E.5.2 | Secondary end point(s) |
1. Percent and absolute change from Baseline to Month 6 in spot urinary oxalate-to-creatinine ratio 2. Plasma PK parameters for nedosiran and/or its metabolites, including Cmax, AUCt and AUC∞ (if estimable) 3. Percentage of participants with spot urinary oxalate-to-creatinine ratio ≤ the ULN and ≤ 1.5 x ULN at any time point through Month 6 4. Change from Baseline in eGFR at Month 6 (only in participants ≥ 12 Months of age at Screening) |
1. Cambio porcentual y absoluto desde el inicio hasta el mes 6 en la proporción oxalato-creatinina de las muestras puntuales de orina 2. Parámetros farmacocinéticos plasmáticos de Nedosiran y/o sus metabolitos, incluido la Cmáx, el área bajo la curva (AUC, en inglés) y el AUC∞ (si puede estimarse) 3. Porcentaje de participantes con una proporción oxalato-cratinina de las muestras puntuales de orina ≤LSN y ≤1,5 x LSN en cualquier punto temporal hasta el mes 6 4. Cambio desde el inicio en la TFGe en el mes 6 (solo en participantes ≥12 meses de edad en la selección) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. The percent and absolute change in average spot urinary oxalate-to creatinine ratio from Baseline to Day 180 will be summarized 2. Pharmacokinetic analyses will be described in the SAP finalized before database lock. The population PK analysis will be presented separately from the main CSR 3. The percentage of participants with spot urinary oxalate-to-creatinine ratio ≤ the ULN and ≤ 1.5 x ULN at any time point through Month 6 will be summarized. 4. The percent change from baseline in eGFR at Month 6 (only in participants ≥ 12 Months of age at Screening) will be summarized. |
1. Se resumira el cambio porcentual y absoluto en la proporcion media de oxalato-creatinina de las muestras puntuales de orina hasta el dia 180 2. Los analisis farmacocineticos seran descritos en el SAP finalizado antes dell cierre de la base de datos. El analisis farmacocineticao poblacional se presentara por separado al Informe final de resultados principal 3. Se resumira el porcentaje de participantes con una proporción oxalato-cratinina de las muestras puntuales de orina ≤LSN y ≤1,5 x LSN en cualquier punto temporal hasta el mes 6 4. Se resumira el cambio desde el inicio en la TFGe en el mes 6 (solo en participantes ≥12 meses de edad en la selección) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 9 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Japan |
Lebanon |
Morocco |
Turkey |
United States |
France |
Germany |
Italy |
Poland |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
A participant is considered to have completed the study if he or she has completed all phases of the study, including the last visit or the last scheduled procedure shown in the Schedule of Activities (SoA), Section 1.3. The end of the study is defined as completion of the last visit or procedure shown in the SoA in the trial globally. |
Se considerara que un participante ha completado el estudio si el o ella ha completado todas las fases del estudio, incluida la última visita o el último procedimiento programado que se muestra en el calendario de actividades (SoA), Sección 1.3. El final del estudio se define como la finalización de la última visita o procedimiento que se muestra en el SoA del ensayo a nivel mundial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |